Pangaea Oncology, S.A. (PANG.MC)

EUR 1.68

(0.0%)

EBITDA Summary of Pangaea Oncology, S.A.

Pangaea Oncology, S.A.'s latest annual EBITDA in 2023 was -1.55 Million EUR , up 8.57% from previous year.
Pangaea Oncology, S.A.'s latest quarterly EBITDA in 2023 FY was N/A , up 8.57% from previous quarter.
Pangaea Oncology, S.A. reported an annual EBITDA of -1.4 Million EUR in 2022, down -421.68% from previous year.
Pangaea Oncology, S.A. reported an annual EBITDA of 146.78 Thousand EUR in 2021, down -46.9% from previous year.
Pangaea Oncology, S.A. reported a quarterly EBITDA of -497.29 Thousand EUR for 2023 Q2, down 0.0% from previous quarter.
Pangaea Oncology, S.A. reported a quarterly EBITDA of -849.91 Thousand EUR for 2023 Q3, down -70.91% from previous quarter.

Annual EBITDA Chart of Pangaea Oncology, S.A. (2023 - 2013)

Historical Annual EBITDA of Pangaea Oncology, S.A. (2023 - 2013)

Year	EBITDA	EBITDA Growth
2023	-1.55 Million EUR	8.57%
2022	-1.4 Million EUR	-421.68%
2021	146.78 Thousand EUR	-46.9%
2020	730.31 Thousand EUR	-12.29%
2019	-1.71 Million EUR	36.21%
2018	739.84 Thousand EUR	187.43%
2017	-903.59 Thousand EUR	-194.46%
2016	-231.69 Thousand EUR	1328.71%
2015	558.92 Thousand EUR	81.63%
2014	-308.95 Thousand EUR	-141.73%
2013	740.36 Thousand EUR	0.0%

Year	EBITDA	EBITDA Growth
2023 Q4	-849.91 Thousand EUR	0.0%
2023 Q2	-497.29 Thousand EUR	0.0%
2023 Q3	-849.91 Thousand EUR	-70.91%
2023 FY	- EUR	8.57%
2023 Q1	-497.29 Thousand EUR	46.39%
2022 FY	- EUR	-421.68%
2022 Q4	-927.59 Thousand EUR	0.0%
2021 FY	- EUR	-46.9%
2020 FY	- EUR	-12.29%
2019 FY	- EUR	36.21%
2018 FY	- EUR	187.43%
2017 FY	- EUR	-194.46%
2016 FY	- EUR	1328.71%
2015 FY	- EUR	81.63%
2014 FY	- EUR	-141.73%
2013 FY	- EUR	0.0%

Peer EBITDA Comparison of Pangaea Oncology, S.A.

Name	EBITDA	EBITDA Difference
Clínica Baviera, S.A.	67.21 Million EUR	102.317%